The psychosis high-risk state: A comprehensive state-of-the-art review

Archives of General Psychiatry

Volumn 70, Issue 1, 2013, Pages 107-120

  Fusar Poli, Paolo ^a,b   Borgwardt, Stefan ^c   Bechdolf, Andreas ^d   Addington, Jean ^e   Riecher Rössler, Anita ^c   Schultze Lutter, Frauke ^f   Keshavan, Matcheri ^g   Wood, Stephen ^h,i   Ruhrmann, Stephan ^d   Seidman, Larry J ^g,j   Valmaggia, Lucia ^a,b   Cannon, Tyrone ^k   Velthorst, Eva ^l   De Haan, Lieuwe ^l   Cornblatt, Barbara ^m   Bonoldi, Ilaria ^a,b   Birchwood, Max ⁱ   McGlashan, Thomas ⁿ   Carpenter, William ^o   McGorry, Patrick ^h   Klosterkötter, Joachim ^d   McGuire, Philip ^a,b   Yung, Alison ^h   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Foundation Trust   (United Kingdom)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF BERN   (Switzerland)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m ZUCKER HILLSIDE HOSPITAL   (United States)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; FISH OIL; MOOD STABILIZER; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; OLANZAPINE; RISPERIDONE;

CLINICAL FEATURE; COGNITION; COGNITIVE THERAPY; DISEASE COURSE; DSM-5; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; NEUROIMAGING; NEUROPROTECTION; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PREDICTION; PRODROMAL SYMPTOM; PROGNOSIS; PSYCHOSIS; REVIEW; RISK FACTOR; SOCIOECONOMICS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; CONSENSUS; RISK; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HELP SEEKING BEHAVIOR; HIGH RISK BEHAVIOR; SOCIAL COGNITION;

CONSENSUS; HUMANS; PSYCHOTIC DISORDERS; RISK;

MLCS; MLOWN;

EID: 84871989449     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.269     Document Type: Review

References (160)

1. Klosterkötter JGG, Huber G, Wieneke A, Steinmeyer EM, Schultze-Lutter F. Evaluation of the Bonn Scale for the Assessment of Basic Symptoms: BSABS as an instrument for the assessment of schizophrenia proneness: a review of recent findings. Neurol Psychiatry Brain Res. 1997;5:137-150.
2. Schultze-Lutter F, Schimmelmann BG, Ruhrmann S. The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull. 2011;37(4):653-655.
3. Fusar-Poli P, Borgwardt S, McGuire P. Vulnerability to Psychosis: From Neurosciences to Psychopathology. London, United Kingdom: Psychology Press; 2011.
4. Fusar-Poli P, Yung AR. Should attenuated psychosis syndrome be included in DSM5? Lancet. 2012;379(9816):591-592.
5. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, HallgrenM, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32.
6. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-799.
7. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to firstepisode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921-928.
8. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-154.
9. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP. Cognitive therapy for the prevention of psychosis in people at ultrahigh risk: randomised controlled trial. Br J Psychiatry. 2004;185:291-297.
10. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill: advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120(1-3):23-37.
11. Carpenter WT Jr. Criticism of the DSM-V risk syndrome: a rebuttal. Cogn Neuropsychiatry. 2011;16(2):101-106.
12. Yung AR, Nelson B, Thompson AD, Wood SJ. Should a "Risk Syndrome for Psychosis" be included in the DSMV? Schizophr Res. 2010;120(1-3):7-15.
13. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res. 2010;120(1-3):16-22.
14. Arango C. Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2011;20(2):67-70.
15. Drake RJ, Lewis SW. Valuing prodromal psychosis: what do we get and what is the price? Schizophr Res. 2010;120(1-3):38-41.
16. Mrazek P, Haggerty H. Reducing Risks for Mental Disorders: Frontiers for Preventive Research. Washington, DC: Academy Press; 1994.
17. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rössler A, Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206-1212.
18. Sullivan HS. The onset of schizophrenia: 1927. Am J Psychiatry. 1994;151(6)(suppl):134-139.
19. Mayer-Gross W. Die Klinik der Schizophrenie. In: Bunke O, ed. Handbuch der Geisteskrankheiten. Vol IX. Berlin, Germany: Springer; 1932.
20. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med. 1989;80(12):646-652.
21. Riecher A, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Häfner H. Schizophrenia: a disease of young single males? preliminary results from an investigation on a representative cohort admitted to hospital for the first time. Eur Arch Psychiatry Neurol Sci. 1989;239(3):210-212.
22. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, van der Heiden W. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992;6(3):209-223.
23. Häfner H, Maurer K, Löffler W, an der Heiden W, Munk-Jørgensen P, Hambrecht M, Riecher-Rössler A. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33(8):380-386.
24. Häfner H, Maurer K, Löffler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993;162:80-86.
25. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W. First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci. 1992;242(2-3):109-118.
26. Jackson HJ, McGorry PD, McKenzie D. The reliability of DSM-III prodromal symptoms in first-episode psychotic patients. Acta Psychiatr Scand. 1994;90(5):375-378.
27. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303.
28. McGlashan TH. Early detection and intervention in schizophrenia: editor's introduction. Schizophr Bull. 1996;22(2):197-199.
29. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370.
30. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull. 1996;22(2):327-345.
31. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996;22(2):305-326.
32. Falloon IR, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull. 1996;22(2):271-282.
33. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia, I: early course parameters. Schizophr Bull. 1996;22(2):241-256.
34. Olin SC, Mednick SA. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull. 1996;22(2):223-240.
35. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull. 1996;22(2):201-222.
36. Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, Hoffman R, Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999;70(4):273-287.
37. McGlashan T, Walsh B, Woods S. The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up. New York, NY: Oxford University Press; 2010.
38. Klosterkötter J, Ebel H, Schultze-Lutter F, Steinmeyer EM. Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):147-154.
39. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, Schimmelmann BG, Klosterkötter J. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18(4):351-357.
40. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull. 2007;33(3):661-664.
41. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: assessment instruments. Acta Psychiatr Scand . 2006;113(4):273-282.
42. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57-66.
43. Carr V, Halpin S, Lau N, O'Brien S, Beckmann J, Lewin T. A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust N Z J Psychiatry. 2000;34(suppl):S170-S180.
44. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29(4):633-651.
45. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkötter J. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010;67(3):241-251.
46. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, Bramon E, McGuire PK. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry. 2005;20(5-6):372-378.
47. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(suppl 3):S162-S167.
48. Simon AE, Dvorsky DN, Boesch J, Roth B, Isler E, Schueler P, Petralli C, Umbricht D. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res. 2006;81(1):83-90.
49. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971.
50. Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, Pflüger M, Radü W, Schindler Ch, Stieglitz RD. The Basel early-detection-of-psychosis (FEPSY)-study: design and preliminary results. Acta Psychiatr Scand. 2007;115(2):114-125.
51. Riecher-Rössler A, Aston J, Ventura J, Merlo M, Borgwardt S, Gschwandtner U, Stieglitz RD. The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity [in German]. Fortschr Neurol Psychiatr. 2008;76(4):207-216.
52. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-715.
53. Loewy RL, Bearden CE, Johnson JK, Raine A, Cannon TD. The Prodromal Questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res. 2005;79(1):117-125.
54. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35(1):5-8.
55. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158-164.
56. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S. Predicting first-episode psychosis by basic symptoms criteria. Clin Neuropsychiatry. 2007;4(1):11-22.
57. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Veith V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Moller H, Gaebel W, Hafner H, Maier W, Klosterkotter J. Preventing progression to firstepisode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200(1):22-29.
58. Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res. 2011;126(1-3):58-64.
59. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome, Italy: Giovanni Fiorito Editore; 2007.
60. Schultze-Lutter F, Marshall M, Koch E. Schizophrenia Proneness Instrument, Child and Youth Version (SPI-CY), Extended English Translation. Rome, Italy: Giovanni Fiorito Editore; 2012.
61. Keshavan MS, DeLisi LE, Seidman LJ. Early and broadly defined psychosis risk mental states. Schizophr Res. 2011;126(1-3):1-10.
62. Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry. 2011;10(3):165-174.
63. Fusar-Poli P, Borgwardt S, Valmaggia L. Heterogeneity in the assessment of the at-risk mental state for psychosis [letter]. Psychiatr Serv. 2008;59(7):813.
64. Nelson B, Fusar-Poli P, Yung AR. Can we detect psychotic-like experiences in the general population? Curr Pharm Des. 2012;18(4):376-385.
65. Ochoa S, Haro JM, Torres JV, Pinto-Meza A, Palacín C, Bernal M, Brugha T, Prat B, Usall J, Alonso J, Autonell J. What is the relative importance of self reported psychotic symptoms in epidemiological studies? results from the ESEMeDCatalonia Study. Schizophr Res. 2008;102(1-3):261-269.
66. Granö N, Karjalainen M, Itkonen A, Anto J, Edlund V, Heinimaa M, Roine M. Differential results between self-report and interview-based ratings of risk symptoms of psychosis. Early Interv Psychiatry. 2011;5(4):309-314.
67. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179-195.
68. Schimmelmann B,Walger P, Schultze-Lutter F. The significance of at-risk symptoms of psychosis in children and adolescents. Can J Psychiatry. In press.
69. Schimmelmann BG, Michel C, Schaffner N, Schultze-Lutter F. What percentage of people in the general population satisfies the current clinical at-risk criteria of psychosis? Schizophr Res. 2011;125(1):99-100.
70. Kelleher I, Murtagh A, Molloy C, Roddy S, Clarke MC, Harley M, Cannon M. Identification and characterization of prodromal risk syndromes in young adolescents in the community: a population-based clinical interview study. Schizophr Bull. 2011;38(2):239-246.
71. Yung AR, Nelson B, Thompson A, Wood SJ. The psychosis threshold in Ultra High Risk (prodromal) research: is it valid? Schizophr Res. 2010;120(1-3):1-6.
72. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172(33):14-20.
73. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: amultisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
74. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton M, Barale F, Caverzasi E, McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69(3):220-229.
75. Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, McGuire P. At risk for schizophrenic or affective psychoses? a meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk [published online May 15, 2012]. Schizophr Bull. doi:10.1093/schbul/sbs060.
76. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57-66.
77. Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L. Ultra highrisk state for psychosis and non-transition: a systematic review. Schizophr Res. 2011;132(1):8-17.
78. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168(8):800-805.
79. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull. 2010;36(1):182-191.
80. Yung A, Nelson B, Yuen H, Spiliotacopoulos D, Lin A, Simmonds HA, Bruxner A, Broussard C, Thompson A, McGorry P. Long term outcome in an ultra high risk ("prodromal") group. Schizophr Bull. 2011;37:22-23.
81. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105(1-3):10-17.
82. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908.
83. Bechdolf A, Pukrop R, Köhn D, Tschinkel S, Veith V, Schultze-Lutter F, Ruhrmann S, Geyer C, Pohlmann B, Klosterkötter J. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res. 2005;79(1):137-143.
84. Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res. 2008;99(1-3):119-124.
85. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68(1):37-48.
86. Velthorst E, Nieman DH, Linszen D, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S. Disability in people clinically at high risk of psychosis. Br J Psychiatry. 2010;197(4):278-284.
87. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K,HeatonR, Keefe RS, Heinssen R, Cornblatt BA; North American Prodrome Longitudinal Study (NAPLS) Group. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578-588.
88. Fusar-Poli P, Byrne M, Valmaggia L, Day F, Tabraham P, Johns L, McGuire P. Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. J Psychiatr Res. 2010;44(5):294-301.
89. Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T. Risk factors for psychosis: impaired social and role functioning [published online November 10, 2011]. Schizophr Bull. doi:10.1093/schbul/sbr136.
90. Ruhrmann S, Paruch J, Bechdolf A, Pukrop R, Wagner M, Berning J, Schultze-Lutter F, Janssen B, Gaebel W, Möller HJ,Maier W, Klosterkötter J. Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatr Scand. 2008;117(5):357-368.
91. Hutton P, Bowe S, Parker S, Ford S. Prevalence of suicide risk factors in people at ultra-high risk of developing psychosis: a service audit. Early Interv Psychiatry. 2011;5(4):375-380.
92. Fusar-Poli P, Deste G, Smieskova R, Barlati G, Yung AR, Howes O, Stieglitz R, McGuire P, Borgwardt S. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69(6):1-10.
93. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry. 2008;165(5):579-587.
94. Giuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des. 2012;18(4):399-415.
95. Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, Broussard C, Pantelis C, Yung AR. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res. 2011;132(1):1-7.
96. Niendam TA, Jalbrzikowski M, Bearden CE. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol Rev. 2009;19(3):280-293.
97. Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA. Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry. 2011;168(8):806-813.
98. Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de Haan L, Linszen DH. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr Res. 2011;125(1):69-76.
99. McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci. 2008;29(2):91-98.
100. Phillips LJ, Velakoulis D, Pantelis C, Wood S, Yuen HP, Yung AR, Desmond P, Brewer W, McGorry PD. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res. 2002;58(2-3):145-158.
101. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: amagnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006;63(2):139-149.
102. Yücel M, Wood SJ, Phillips LJ, Stuart GW, Smith DJ, Yung A, Velakoulis D, McGorry PD, Pantelis C. Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. Br J Psychiatry. 2003;182:518-524.
103. Wood SJ, Yung AR, McGorry PD, Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry. 2011;70(7):619-625.
104. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361(9354):281-288.
105. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rössler A, Borgwardt SJ. Neuroimaging predictors of transition to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2010;34(8):1207-1222.
106. Mechelli A, Riecher-Rössler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, Koutsouleris N, Yung AR, Stone JM, Phillips LJ, McGorry PD, Valli I, Velakoulis D, Woolley J, Pantelis C, McGuire P. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 2011;68(5):489-495.
107. Koutsouleris N, Meisenzahl EM, Davatzikos C, Bottlender R, Frodl T, Scheuerecker J, Schmitt G, Zetzsche T, Decker P, Reiser M, Möller HJ, Gaser C. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry. 2009;66(7):700-712.
108. Broome MR, Matthiasson P, Fusar-Poli P, Woolley JB, Johns LC, Tabraham P, Bramon E, Valmaggia L, Williams SC, Brammer MJ, Chitnis X, McGuire PK. Neural correlates of executive function and workingmemory in the "at-risk mental state." Br J Psychiatry. 2009;194(1):25-33.
109. Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry. 2005;62(3):254-262.
110. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK; OASIS. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 2009;66(6):533-539.
111. Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, Desmond P, Pantelis C. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull. 2003;29(4):831-843.
112. Jessen F, Scherk H, Träber F, Theyson S, Berning J, Tepest R, Falkai P, Schild HH, Maier W, Wagner M, Block W. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res. 2006;87(1-3):81-88.
113. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13-20.
114. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011;168(12):1311- 1317.
115. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F]/[11C]-DOPA PET studies [published online January 26, 2012]. Schizophr Bull. doi:10.1093/schbul/sbr180.
116. Bodatsch M, Ruhrmann S, Wagner M, Müller R, Schultze-Lutter F, Frommann I, Brinkmeyer J, Gaebel W, Maier W, Klosterkötter J, Brockhaus-Dumke A. Prediction of psychosis by mismatch negativity. Biol Psychiatry. 2011;69(10):959-966.
117. Zimmermann R, Gschwandtner U, Wilhelm FH, Pflueger MO, Riecher-Rössler A, Fuhr P. EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophr Res. 2010;123(2-3):208-216.
118. Fusar-Poli P, Radua J,McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies [published online November 17, 2011]. Schizophr Bull. doi:10.1093/schbul/sbr134.
119. Fusar-Poli P, Borgwardt S, Crescini A, Deste G, Kempton MJ, Lawrie S, Mc Guire P, Sacchetti E. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev. 2011;35(5):1175-1185.
120. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, Cortesi M, Veggiotti P, Politi P, Barale F, McGuire P. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2007;31(4):465-484.
121. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry. 2007;51:s13-s18.
122. Stone JM. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des. 2009;15(22):2594-2602.
123. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: meta-analysis of dopamine active transporter (DAT) density [published online January 26, 2012]. Schizophr Bull. doi:10.1093/schbul/sbr111.
124. Fusar-Poli P, McGuire P, Borgwardt S. Mapping prodromal psychosis: a critical review of the literature. Eur Psychiatry. 2012;27(3):181-191.
125. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Montgomery AJ, Grasby PM, McGuire P. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 2011;16(1):67-75.
126. Fusar-Poli P, Stone J, Broome M, Valli I, Mechelli A, McLean M, Lythgoe D, O'Gorman R, Barker G, McGuire P. Thalamic glutamate levels predicts cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry. 2011;68(9):881-890.
127. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC, Grasby PM, McGuire PK. Abnormal frontostriatal interactions in peoplewith prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry. 2010;67(7):683-691.
128. Riecher-Rössler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, Stieglitz RD. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry. 2009;66(11):1023-1030.
129. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with "at-risk mental states." Schizophr Res. 2004;71(2-3):227-237.
130. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142.
131. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the "at risk" for psychosis population: international comparisons with results from the North American Prodrome Longitudinal Study. Schizophr Res. 2011;126(1-3):51-57.
132. Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. Disorganization/ cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr Bull. 2010;38(2):351-359.
133. Keshavan MS, Vora A, Montrose D, Diwadkar VA, Sweeney J. Olfactory identification in young relatives at risk for schizophrenia. Acta Neuropsychiatr. 2009;21(3):121-124.
134. van Tricht MJ, Nieman DH, Koelman JH, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, de Haan L. Auditory ERP components before and after transition to a first psychotic episode. Biol Psychol. 2011;87(3):350-357.
135. Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, Gaser C, Möller HJ, Meisenzahl EM. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification [published online May 16, 2011]. Schizophr Bull. doi:10.1093/schbul/sbr037.
136. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res. 2010;123(1):30-36.
137. Morrison AP, Stewart SL, French P, Bentall RP, Birchwood M, Byrne R, Davies LM, Fowler D, Gumley AI, Jones PB, Lewis SW, Murray GK, Patterson P, Dunn G. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Interv Psychiatry. 2011;5(1):24-32.
138. Rietdijk J, Dragt S, Klaassen R, Ising H, Nieman D, Wunderink L, Delespaul P, Cuijpers P, Linszen D, van der Gaag M. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials. 2010;11:30.
139. Bechdolf A, Müller H, Stützer H, Wagner M, Maier W, Lautenschlager M, Heinz A, de Millas W, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Brüne M, Krüger-Özgürdal S, Wobrock T, Riedel M, Klosterkötter J; PREVENT Study Group. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating
140. Yung AR, Phillips JL, Nelson B, Francey S, Panyuen H, Simmons M, Rossi M, Kelly D, Baker K, Amminger GP, Berger G, Thompson A, Thampi A, McGorry PD. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry. 2011;72(4):430-440.
141. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54-61.
142. Phillips LJ, McGorry PD, Yuen HP,Ward J, Donovan K, Kelly D, Francey SM, Yung AR. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res. 2007;96(1-3):25-33.
143. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, Lewis SW. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull. 2007;33(3):682-687.
144. Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry. 2010;44(3):230-236.
145. Phillips LJ, Cotton S, Mihalopoulos C, Shih S, Yung AR, Carter R, McGorry PD. Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv Psychiatry. 2009;3(1):28-34.
146. Valmaggia LR, McCrone P, Knapp M, Woolley JB, Broome MR, Tabraham P, Johns LC, Prescott C, Bramon E, Lappin J, Power P, McGuire PK. Economic impact of early intervention in people at high risk of psychosis. Psychol Med. 2009;39(10):1617-1626.
147. Mihalopoulos C, McGorry PD, Carter RC. Is phase-specific, communityoriented treatment of early psychosis an economically viable method of improving outcome? Acta Psychiatr Scand. 1999;100(1):47-55.
148. Bosanac P, Patton GC, Castle DJ. Early intervention in psychotic disorders: faith before facts? Psychol Med. 2010;40(3):353-358.
149. McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, Penn D, Perkins D, Salokangas RK, Walsh B, Woods SW, Yung A. Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull. 2007;33(3):715-726.
150. Yung AR. Risk, disorder and diagnosis. Aust N Z J Psychiatry. 2011;45(11):915-919.
151. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128-137.
152. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, Lieberman JA. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry. 2005;186:26-31.
153. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry. 2010;55(8):486-497.
154. Fusar-Poli P, Borgwardt S. Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. Med Hypotheses. 2007;69(4):959-960.
155. Kessler RC, Price RH. Primary prevention of secondary disorders: a proposal and agenda. Am J Community Psychol. 1993;21(5):607-633.
156. Thompson AD, Bartholomeusz C, Yung AR. Social cognition deficits and the "ultra high risk" for psychosis population: a review of literature. Early Interv Psychiatry. 2011;5(3):192-202.
157. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet. 2007;370(9601):1746-1748.
158. Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, Phillips L, Nelson B, Amminger GP, Yung AR, Jackson G, Velakoulis D, Pantelis C, Manji H, McGorry PD. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis: a longitudinal MRI/MRS study. Curr Pharm Des. 2012;18(4):570-575.
159. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78-86.
160. Yung AR, Woods S, Ruhrman S, Addington J, Schultze-Lutter F, Cornblatt B, Amminger P, Bechdolf A, Birchwood M, Borgwardt S, Cannon T, de Haan L, French P, Fusar-Poli P, Keshavan M, Klosterkoetter L, Kwon JS, McGorry P, McGuire P, Mizuno M, Morrison A, Riecher A, Salokangas R, Seidman L, Suzuki M, Valmaggia L, van der Gaag M, Wood SJ, McGlashan TH. Whither the attenuated psychosis syndrome? Schizophr Bull. In press.